MDMA
MindMed Advances Medical LSD Studies for Anxiety, Autism with $177M in the Bank
The company said it has enough cash to continue operations into 2026.
The post MindMed Advances Medical LSD Studies for Anxiety, Autism with $177M in the…
Mind Medicine Inc. (NASDAQ: MNMD), (NEO: MMED), which does business as MindMed, is still in the pre-revenue stage but is getting ever-closer to bringing its version of LSD to market to treat anxiety patients.
The company announced that more phase two trial data is expected in the fourth quarter this year and proof-of-concept data by the close of Q1 next year.
In its third quarter financials released Thursday, the psychedelics firm reported a $17.9 million net loss for the period ended Sept. 30, up from the $16.5 million loss posted in the same quarter last year.
But MindMed also reported having $117.7 million in the bank, which it said should fund ongoing trials and other research work “into 2026, if certain milestones are achieved that unlock additional capital.”
So far in 2023, MindMed has burned through $43.8 million in operating expenses, including $6.4 million spent on the studies of MM-120, MindMed’s version of LSD that it’s using to treat patients with generalized anxiety disorder in trials.
MindMed is expecting data from a 198-patient study of MM-120 to be announced before the end of the year, and “safety and efficacy results” to be released in Q1 next year. In the separate proof-of-concept study, which involved 53 patients, results are also expected in Q1 2024.
The company is also actively working on research and trials for a version of MDMA, called MM-402, designed to help treat autism spectrum disorder. Its first clinical trial is slated to begin in Q4 this year at a hospital in Switzerland, with data expected in the first half of next year.
“The continued growth in prevalence and impact of (generalized anxiety disorder), (autism spectrum disorder) and other brain health disorders highlights the importance and timeliness of our innovative programs. Our team remains singularly focused on delivering novel treatments for brain health disorders to the millions of patients in need, and we are eager to share these important milestones in the months ahead,” said MindMed CEO Robert Barrow in a statement.
The post MindMed Advances Medical LSD Studies for Anxiety, Autism with $177M in the Bank appeared first on Green Market Report.
mdma lsd anxiety psychedelics fund nasdaq capital mind medicine mindmed research
-
Law & Regulation1 week agoClearmind signs agreement with Hebrew University for psychedelic compound rights
-
Psychedelics1 week agoCybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
-
Psilocybin1 week agoCalifornia advances bill for psychedelics centers
-
Psilocybin4 days agoPassover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week agoPsychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics1 week agoRevive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
-
Psychedelics4 days agoAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics4 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID